ArticleCell reports2022

Phosphoproteomics of primary AML patient samples reveals rationale for AKT combination therapy and p53 context to overcome selinexor resistance.

Kristina B Emdal et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.